Flavopiridol hydrochloride

Key Product Details

Product Description

Flavopiridol hydrochloride is a cyclin-dependent kinase (cdk) inhibitor (reported IC₅₀ values are 6 - 25 nM and 84 - 200 nM for cdk9 and cdk2, respectively, and <0.85 μM for cdk1, cdk4, cdk5 and cdk7). Induces cell cycle arrest at G1 and G2 phase. Potently inhibits the growth of breast and lung cancer cell lines (IC₅₀ = 25 - 160 nM) in vitro.

Product Specifications for Flavopiridol hydrochloride

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Flavopiridol hydrochloride

The following data is based on the product molecular weight 438.30.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.28 mL	11.41 mL	22.82 mL
5 mM	0.46 mL	2.28 mL	4.56 mL
10 mM	0.23 mL	1.14 mL	2.28 mL
50 mM	0.05 mL	0.23 mL	0.46 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 10 publications citing the usage of this product.

• Jorda How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases? J.Med.Chem. 2018 PMID: 30234987
• Ambrosini The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res. 2008 PMID: 18381438
• Losiewicz Potent inhibition of Cdc2 kinase activity by the flavonoid L86-8275. Biochem.Biophys.Res.Comm.
• Kaur Growth inhibition with reversible cell cycle arrest of carcinoma cells by Flavone L86-8275. J.Natl.Cancer.Inst. 1992 PMID: 1279187

Product Documents for Flavopiridol hydrochloride